TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33601293

Group type: EXPERIMENTAL
Intervention: Depatux‐M 1.25 mg/kg with oral temozolomide (TMZ) 150 mg/m2
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Depatux‐M 1.0 mg/kg with oral temozolomide (TMZ) 150 mg/m2
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Depatux‐M alone
Number of subjects: 260

Group type: COMPARATOR
Intervention: TMZ or oral lomustine (CCNU) 110 mg/m2 (TMZ/CCNU)
Number of subjects: 260
Study: 33317453

Group type: EXPERIMENTAL
Intervention: Pre-thickened oral nutritional supplements (ONS) with standard OD and nutritional care.
Number of subjects: 156

Group type: COMPARATOR
Intervention: Standard OD and nutritional care (Control).
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Pre-thickened ONS with standard OD and nutritional care.
Number of subjects: 156
Study: 36763994

Group type: EXPERIMENTAL
Intervention: OC‐01 (varenicline solution) 0.03 mg
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: OC‐01 (varenicline solution) 0.06 mg
Number of subjects: 891

Group type: COMPARATOR
Intervention: Vehicle control (VC)
Number of subjects: 891
Study: 32438071

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urinary metabolites
Number of subjects: 0
Study: 36388808

Group type: EXPERIMENTAL
Intervention: Megestrol acetate dispersible tablets with a 5-HT3 receptor antagonist and dexamethasone
Number of subjects: 120

Group type: COMPARATOR
Intervention: 5-HT3 receptor antagonist plus dexamethasone
Number of subjects: 120
Study: 32786187

Group type: EXPERIMENTAL
Intervention: Azacitidine plus Venetoclax
Number of subjects: 431

Group type: COMPARATOR
Intervention: Azacitidine plus Placebo (Control)
Number of subjects: 431
Study: 35436644

Group type: EXPERIMENTAL
Intervention: Induction of labor (IOL) at 39 weeks
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Induction of labor (IOL) at 39 weeks (subgroup)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Expectant management (EM)
Number of subjects: 380
Study: 33586201

Group type: EXPERIMENTAL
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 27635

Group type: EXPERIMENTAL
Intervention: Academic Programs (ALND adherence)
Number of subjects: 27635

Group type: EXPERIMENTAL
Intervention: Community Cancer Programs (ALND adherence)
Number of subjects: 27635

Group type: EXPERIMENTAL
Intervention: ALND
Number of subjects: 27635

Group type: EXPERIMENTAL
Intervention: Positive SLN
Number of subjects: 27635
Study: 35196033

Group type: EXPERIMENTAL
Intervention: AAR + multimodal behavioral intervention (MBI)
Number of subjects: 396

Group type: COMPARATOR
Intervention: AAR + control
Number of subjects: 396

Group type: EXPERIMENTAL
Intervention: AAR + MBI
Number of subjects: 396
Study: 34869163

Group type: EXPERIMENTAL
Intervention: Non-pharmacological intervention delivered through Junior Public Health Nurses (JPHNs) with additional module-based training.
Number of subjects: 132

Group type: COMPARATOR
Intervention: Standard management continued in the control group.
Number of subjects: 132
Study: 33830462

Group type: EXPERIMENTAL
Intervention: Fully cemented TKA + intra‐articular injection (IAI) of 1 g TXA (n = 54)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Fully cemented TKA + intra‐articular injection (IAI) of 2 g TXA (n = 60)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Reverse hybrid TKA + intra‐articular injection (IAI) of 1 g TXA (n = 56)
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Reverse hybrid TKA + intra‐articular injection (IAI) of 2 g TXA (n = 63)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 233
Study: 35218673

Group type: EXPERIMENTAL
Intervention: paclitaxel‐epirubicin‐carboplatin (TEC)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: paclitaxel‐anthracycline (doxorubicin)‐carboplatin (TAC)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: dose‐dense paclitaxel‐carboplatin (ddTC)
Number of subjects: 101
Study: 32755372

Group type: EXPERIMENTAL
Intervention: Normoxic management (35% oxygen during anesthetic induction, 35% during hypothermic bypass, 45% during rewarming)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Hyperoxic management (70% oxygen during anesthetic induction, 50% during hypothermic bypass, 70% during rewarming)
Number of subjects: 48
Study: 34965609

Group type: EXPERIMENTAL
Intervention: Cetagliptin 50 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cetagliptin 100 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cetagliptin 200 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Sitagliptin 100 mg (positive control)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cetagliptin (doses ≥50 mg)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cetagliptin (all doses)
Number of subjects: 48
Study: 32115735

Group type: EXPERIMENTAL
Intervention: 1% Milk sphingolipid-enriched fraction (MSEF) cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Base cream (vehicle)
Number of subjects: 0
Study: 33811039

Group type: COMPARATOR
Intervention: Highly aspherical lenslets (HAL)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Slightly aspherical lenslets (SAL)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Single-vision spectacle lenses (SVL)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: All groups (HAL, SAL, SVL)
Number of subjects: 170
Study: 33709302

Group type: EXPERIMENTAL
Intervention: Tablet-based intervention (daily self-care for pain, distress, fatigue, and sleep disturbance; weekly calls with a patient navigator)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Tablet-based intervention
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Nurse AMIE (cost of delivering the intervention)
Number of subjects: 17
Study: 32763585

Group type: EXPERIMENTAL
Intervention: Escitalopram (ESC) + Celecoxib (CBX)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Escitalopram (ESC) + Placebo (PBO)
Number of subjects: 47
Study: 37052645

Group type: EXPERIMENTAL
Intervention: Aberdeen Home Continence Stress Test (HCST)
Number of subjects: 600

Group type: COMPARATOR
Intervention: 24-hour pad test
Number of subjects: 600
Study: 33392946

Group type: EXPERIMENTAL
Intervention: Home-based pencil push-up therapy (PPT) for 6 weeks, 15 minutes per day
Number of subjects: 176

Group type: COMPARATOR
Intervention: Office-based orthoptic therapy (OBOT) for 6 weeks, 20 minutes per day, 3 days a week
Number of subjects: 176
Study: 36385018

Group type: EXPERIMENTAL
Intervention: My Kidneys & Me (digital self-management programme) in addition to usual care
Number of subjects: 432

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: Substudy measuring physiological changes (e.g., muscle mass, physical function) and patient experience (qualitative semi-structured interviews)
Number of subjects: 432
Study: 32590214

Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavior therapy (TF-CBT)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Therapy-as-usual (TAU)
Number of subjects: 156
Study: 34595903

Group type: EXPERIMENTAL
Intervention: HyFlex EDM OneFile
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: OneCurve (25/06)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: WaveOne Gold Primary
Number of subjects: 45
Study: 32958584

Group type: EXPERIMENTAL
Intervention: Surgical excision with standard care
Number of subjects: 260

Group type: COMPARATOR
Intervention: Standard care (smoking counseling, follow-up visits every 6 months, control biopsy when indicated)
Number of subjects: 260
Study: 35980349

Group type: COMPARATOR
Intervention: Nivolumab monotherapy (arm A)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Nivolumab + docetaxel (arm B)
Number of subjects: 128
Study: 33869634

Group type: EXPERIMENTAL
Intervention: Daily oral PrEP
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Long-acting injectable (LAI) PrEP
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Awareness of PrEP
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: General willingness to use PrEP
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Factors associated with awareness of PrEP
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Factors associated with willingness to use PrEP
Number of subjects: 550
Study: 32844586

Group type: EXPERIMENTAL
Intervention: Fermented dairy products (cheese, sour cream)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Non-fermented dairy products (butter, whipped cream)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cheese
Number of subjects: 47
Study: 36343881

Group type: EXPERIMENTAL
Intervention: Cancer screening interventions (breast, cervix, colorectal)
Number of subjects: 88
Study: 34648868

Group type: EXPERIMENTAL
Intervention: Frontal theta band tACS
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Parietal theta band tACS
Number of subjects: 137

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Alpha band tACS
Number of subjects: 137
Study: 35512466

Group type: EXPERIMENTAL
Intervention: HF‐rPMS
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham rPMS
Number of subjects: 30
Study: 34535474

Group type: EXPERIMENTAL
Intervention: Aerobic training
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Strength training
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Mixed training (aerobic + strength)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 105
Study: 35831180

Group type: EXPERIMENTAL
Intervention: iCanQuit - 4-week users
Number of subjects: 2415

Group type: EXPERIMENTAL
Intervention: iCanQuit - 26-week users
Number of subjects: 2415

Group type: EXPERIMENTAL
Intervention: QuitGuide - 3-week users
Number of subjects: 2415
Study: 33309947

Group type: EXPERIMENTAL
Intervention: E‐Health+ (TAU plus E‐Health)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 400
Study: 36539602

Group type: COMPARATOR
Intervention: Traditional hydration (Group I) at a rate of 1 ml/kg/h for 24 h
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Modified hydration (Group II) at a rate of 3 ml/kg/h for the first 4 h, then reduced to 1 ml/kg/h for 12 h
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Both groups (I and II)
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: CA‐AKI
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Modified hydration
Number of subjects: 438
Study: 34137530

Group type: EXPERIMENTAL
Intervention: Oral Deferasirox
Number of subjects: 37

Group type: COMPARATOR
Intervention: Intravenous Deferioxamine
Number of subjects: 37
Study: 32083679

Group type: EXPERIMENTAL
Intervention: USDA food safety video intervention (3 minutes)
Number of subjects: 383
Study: 36426200

Group type: EXPERIMENTAL
Intervention: app‐delivered ACT
Number of subjects: 147

Group type: COMPARATOR
Intervention: app‐delivered mindfulness
Number of subjects: 147

Group type: COMPARATOR
Intervention: waitlist group
Number of subjects: 147
Study: 32627859

Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study: 33524311

Group type: EXPERIMENTAL
Intervention: SCB-2019 (3 µg, 9 µg, or 30 µg) with AS03 adjuvant
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: SCB-2019 (3 µg, 9 µg, or 30 µg) with CpG/Alum adjuvant
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: SCB-2019 with no adjuvant
Number of subjects: 148

Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 148
Study: 33112661

Group type: EXPERIMENTAL
Intervention: Digital system for electronic patient-reported outcomes (ePROs) administered weekly by web or automated telephone system
Number of subjects: 496
Study: 33021143

Group type: EXPERIMENTAL
Intervention: Novel, integrated cognitive-behavioral therapy (CBT) for PTSD/SUD
Number of subjects: 37

Group type: COMPARATOR
Intervention: Standard cognitive-behavioral therapy (CBT) for SUD
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both treatment conditions
Number of subjects: 37
Study: 32894159

Group type: EXPERIMENTAL
Intervention: Progressive exercise (up to 6 physiotherapy sessions)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best practice advice (one physiotherapy session)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subacromial corticosteroid injection then progressive exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Subacromial corticosteroid injection then best practice advice
Number of subjects: 0
Study: 616505842

Group type: EXPERIMENTAL
Intervention: Combined supplementation of 160 mug/d Cr plus 200 mg/d Mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: 160 mug/d Cr
Number of subjects: 120

Group type: COMPARATOR
Intervention: 200 mg/d Mg
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 120
Study: 36131325

Group type: EXPERIMENTAL
Intervention: Azithromycin (10-day intravenous treatment)
Number of subjects: 799

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 799

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 799
Study: 32447409

Group type: EXPERIMENTAL
Intervention: Anodal HD-tDCS (2 mA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal HD-tDCS (2 mA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cathodal HD-tDCS (1 mA)
Number of subjects: 0
Study: 33478522

Group type: EXPERIMENTAL
Intervention: CR + SB (20g of CR + 0.5g·kg‐1·d‐1 of SB)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CR
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SB
Number of subjects: 40

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 40

Group type: COMPARATOR
Intervention: CON
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study: 37907899

Group type: EXPERIMENTAL
Intervention: Primary Care Behavioral Health (PCBH) implementation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Traditional primary care (control)
Number of subjects: 17
Study: 33491608

Group type: EXPERIMENTAL
Intervention: Body part videos (AOT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Whole body video (AOT)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Scenery video (AOT)
Number of subjects: 11
Study: 32170802

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS, 2 mA) for 20 minutes
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham transcranial direct current stimulation
Number of subjects: 12
Study: 34050681

Group type: EXPERIMENTAL
Intervention: DPBM with EMD (test group)
Number of subjects: 34

Group type: COMPARATOR
Intervention: DPBM alone (control group)
Number of subjects: 34
Study: 35501967

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 149

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 149
Study: 33496261

Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Antipsychotic medication
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 61
Study: 34817270

Group type: EXPERIMENTAL
Intervention: Branched-chain amino acids (BCAA)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Flavored water (placebo)
Number of subjects: 10
Study: 34319552

Group type: EXPERIMENTAL
Intervention: Favipiravir and hydroxychloroquine combination therapy
Number of subjects: 254

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 254
Study: 33555602

Group type: EXPERIMENTAL
Intervention: Headache at ED presentation
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Being under the influence of drugs or alcohol at the time of injury
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Injury occurring via bike or motor vehicle collision
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: History of anxiety or depression
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Numbness or tingling at ED presentation
Number of subjects: 241
Study: 32729273

Group type: EXPERIMENTAL
Intervention: Remote ischemic pre-conditioning (RIPC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (cuff inflated to 10 mm Hg below SBP)
Number of subjects: 26
Study: 35045053

Group type: EXPERIMENTAL
Intervention: True stimulation
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 17
Study: 34819298

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin glargine 100 units/mL
Number of subjects: 0
Study: 36456986

Group type: EXPERIMENTAL
Intervention: Group DF (full arch digital scans with Medit i700 IOS)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Group CF (full arch PVS impressions)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Group DQ (quadrant arch digital scans with Medit i700 IOS)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Group CQ (quadrant arch PVS impressions)
Number of subjects: 9
Study: 34334297

Group type: EXPERIMENTAL
Intervention: Lobe-specific lymph node dissection (LSND)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Systematic lymph node dissection (SND)
Number of subjects: 0
Study: 35729675

Group type: EXPERIMENTAL
Intervention: Synbiotic supplementation (500 mg of L.acidophilus, L.plantarum, L.fermentum, L.Gasseri and 38.5 mg of fructo‐oligo‐saccharides) for 6 weeks
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 90
Study: 32580803

Group type: EXPERIMENTAL
Intervention: 0.17% nPP
Number of subjects: 504

Group type: EXPERIMENTAL
Intervention: Increasing dietary nPP levels
Number of subjects: 504

Group type: COMPARATOR
Intervention: 0.12% nPP, 3.8% calcium, 2415 IU/kg vitamin D3, 2000 FTU/kg phytase
Number of subjects: 504
Study: 35714273

Group type: EXPERIMENTAL
Intervention: Inactivated enterovirus 71 (EV71) vaccine, administered in two doses on day 0 and 28
Number of subjects: 3000
Study: 33341239

Group type: EXPERIMENTAL
Intervention: Cisplatin plus radiotherapy (CRT)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Radiotherapy alone (RT)
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Baseline Karnofsky performance status (KPS) <90%
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Baseline hemoglobin <10 mg/dL
Number of subjects: 146
Study: 32163672

Group type: EXPERIMENTAL
Intervention: Non-invasive telemedical care (NITC)
Number of subjects: 2248

Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 2248
Study: 35431966

Group type: EXPERIMENTAL
Intervention: Osimertinib plus Yiqi-Yangyin-Jiedu decoction (O+YYJD)
Number of subjects: 314

Group type: COMPARATOR
Intervention: Osimertinib plus placebo (O+placebo)
Number of subjects: 314
Study: 34129232

Group type: EXPERIMENTAL
Intervention: Probiotic supplement containing Lactobacillus acidophilus and Bifidobacterium animalis lactis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 33494374

Group type: EXPERIMENTAL
Intervention: Treatment with DAPI at a concentration of 10 µg/mL in 0.02% saponin or 0.1% Tween‐20 containing Hanks balanced salt solution for 30 min at room temperature
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Immunocytochemical examination to visualize serotonin distribution
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment with alkaline phosphatases
Number of subjects: 0
Study: 34971222

Group type: EXPERIMENTAL
Intervention: Telemedicine remote cognitive testing
Number of subjects: 60

Group type: COMPARATOR
Intervention: Face-to-face cognitive testing
Number of subjects: 60
Study: 32628146

Group type: EXPERIMENTAL
Intervention: Immediate revascularization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initially conservative treatment
Number of subjects: 0
Study: 35672178

Group type: EXPERIMENTAL
Intervention: FluCyD-vac (9 μg of HA/strain and 20% w/v of HP-β-CyD)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Flu-vac (15 μg of HA/strain)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: FluCyD-vac
Number of subjects: 36
Study: 34601838

Group type: EXPERIMENTAL
Intervention: SVV 9% group (liberal fluid therapy with SVV ≤9%)
Number of subjects: 80

Group type: COMPARATOR
Intervention: SVV 14% group (restrictive fluid therapy with SVV ≤14%)
Number of subjects: 80
Study: 32690591

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery
Number of subjects: 549

Group type: COMPARATOR
Intervention: Laparotomy
Number of subjects: 549
Study: 35435426

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Remifentanil
Number of subjects: 80
Study: 33427765

Group type: EXPERIMENTAL
Intervention: 15 mg/kg ibalizumab q2wk
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: 10 mg/kg ibalizumab weekly for 9 weeks, then q2wk
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 34189992

Group type: EXPERIMENTAL
Intervention: MYmind program (n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Wait-list group (n=15)
Number of subjects: 30
Study: 33534427

Group type: EXPERIMENTAL
Intervention: 1,000 mg of borage oil rich in gamma-linolenic acid + vitamin E (drug)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Only vitamin E (placebo)
Number of subjects: 96
Study: 32342562

Group type: EXPERIMENTAL
Intervention: Genome Sequencing (GS) immediately with concurrent standard of care (SoC) testing
Number of subjects: 34

Group type: COMPARATOR
Intervention: Genome Sequencing (GS) delayed after 4 months of standard of care (SoC) testing
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Immediate GS group
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combined GS and SoC approaches
Number of subjects: 34
Study: 35874588

Group type: EXPERIMENTAL
Intervention: Threshold Inspiratory Muscle Training (IMT) - 30 inspiratory breaths at 40% of baseline maximal inspiratory pressure (MIP) twice daily for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Incentive Spirometry (IS) - 30 breaths with sustained maximum inspiration twice daily for 8 weeks
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group - no training device for 8 weeks
Number of subjects: 60
Study: 33399410

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (topical glyceryl trinitrate)
Number of subjects: 44